Trimetazidine has an antianginal, antihypoxic effect. Directly affecting the cardiomyocytes and neurons of the brain, it optimizes their metabolism and function. The cytoprotective effect is due to an increase in the energy potential, activation of oxidative decarboxylation, and rationalization of oxygen consumption (enhancement of aerobic glycolysis and fat oxidation blockade). Supports contractility of the myocardium, prevents the decrease in intracellular content of ATP and phosphocreatinine. In the conditions of acidosis normalizes the functioning of ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, normalizes the intracellular content of potassium ions.
Reduces intracellular acidosis and phosphate concentration, caused by myocardial ischemia and reperfusion.Prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic zone, prolongs the duration of the electrical potential, reduces the yield of creatine phosphokinase of cells and the severity of myocardial ischemic damage.When the frequency of attacks of angina reduces (decreases nitrate consumption) after 2 weeks of treatment increases exercise capacity, reduced blood pressure drops. The hearing and results of vestibular samples in patients improve, dizziness and tinnitus decrease.
In vascular pathology, the eye restores the functional activity of the retina.